Taiho, Memorial Sloan Kettering Cancer Center and Hartford HealthCare contributed to a round that boosted the cancer drug developer's total funding to more than $175m.

US-based oncology drug developer Oric Pharmaceuticals has closed a $55m series D round that included pharmaceutical company Taiho, cancer researcher Memorial Sloan Kettering Cancer Center and healthcare provider Hartford HealthCare. Investment firms Arrowmark Partners and Invus Opportunities co-led the round, which included  financial services and investment group Fidelity Management & Research (FMR), Casdin Capital, The…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.